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Summary
Chlamydia trachomatis serovars A, B, and C are the causative agents of trachoma, the world's
leading cause of preventable blindness. Immunoprophylaxis is a possible approach to control
trachoma. The chlamydial major outer membrane protein (MOMP) is thought to play an important
role in the development of protective immunity against chlamydial infection, and is therefore
considered to be a promising candidate antigen in the development of a trachoma vaccine. Much
effort has been focused on the molecular characterization of B cell sites of the MOMP that elicit
neutralizing antibodies. Neutralizing sites have been identified as linear epitopes that reside within
variable domains (VDs) of the protein whose primary sequences vary among different serovars.
No information exists on MOMP T helper (Th) cell antigenic determinants, which are likely
critical componentsfor the development of a successful chlamydial vaccine. We used overlapping
synthetic peptides (25 mers) representing the entire primary sequence of serovar A MOMP in
T cell proliferation assays to identify T cell antigenic determinants ofthis molecule. Eightsynthetic
peptides (A-2, A-3, A-7, A-8, A-11, A-22, A-23, and A-24) stimulated proliferative responses
of splenic T cells isolated from MOMP-immunized A/J mice. To ascertain if these peptides
functionedas Th cell antigens, we determined their ability to prime A/J mice in vivo to produce
an anamnestic IgG response specific to the MOMP Mice primed with synthetic peptides A-8
(106-130) or A-23 (331-355) produced IgG antibodies reactive with the native MOMP and with
the synthetic peptides corresponding to surface-accessible serovar-specific epitopes located in VD I
and serogroup-specific epitopes located in VD IV of the protein. We synthesized the A-8 and
A-23 peptides with the VD I sequence as colinear chimeric peptides. Immunization of mice with
the T/B cell peptides produced high titered antibodies against the VD I sequence, and these
antibodies reacted with the native MOMP and intact chlamydae. The MOMP sequences containing
these Th cell epitopes are conserved among the MOMP genes of different C. trachomatis serovars,
indicating that they are common Th cell antigenic sites. Thus, the Th cell epitopes contained
within these peptides, in combination with different trachoma serovar-specific B cell neutralizing
determinants, may be useful in the development of a synthetic or recombinant trivalent trachoma
vaccine.
Chlamydia trachomatis serovars A, B, and C are the etio-
logic agents of trachoma; the world's leading cause
of preventable blindness (1). Measures for the prevention or
control ofblindness due to trachoma are needed, and immu-
noprophylaxis is considered to be a possible means for accom-
plishing this goal. Early vaccination attempts in humans using
parenterally administered, noninfectious bacteria were ineffec-
tive and, in fact, proved to be deleterious in that they prompted
a more severe disease that was attributed to vaccine-induced
hypersensitivity (2-4). These difficulties, combined with a
limited knowledge about chlamydialantigenic structure and
host immune responses to chlamydial antigens, impaired fur-
ther progress toward the development of a trachoma vaccine.
Recently, significant progress in understanding immunity
to chlamydial infection has restored both the interest in and
the feasibility ofthe development ofa trachoma vaccine. Ocular
chlamydial infection in guinea pigs and nonhuman primates
induces both protective and deleterious immune responses,
and the antigens that elicit these responses are distinct. The
deleterious immune response is cell mediated and character-
ized as a delayed hypersensitivity response (5, 6). The an-
tigen that elicits deleterious delayed hypersensitivity is common
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203-212to the genus and has been identified as a 57-kD chlamydial
stress-response protein (7, 8). Conversely, protective immu-
nity to ocular infections is largelyserovar specific (9-11). Al-
though the immune mechanism(s) that functions in protec-
tion is unknown, resistance to infection correlates with the
presence ofneutralizing serovar-specific IgAantibodies in tears
(12, 13) suggesting that secretory antibody plays a critical
role in protective immunity. The chlamydial major outermem-
brane protein (MOMP)t is considered to be important in
protective immunity sinceit contains antigenicdeterminants
that elicit serovar-specific neutralizing antibodies (14). Thus,
current trachoma vaccine strategies are focused on the devel-
opment of recombinant or synthetic peptide MOMP vac-
cinesthat induce serovar-specific mucosal immunity andcir-
cumvent sensitization with chlamydial antigens that evoke
deleterious immune responses.
The MOMP genes of trachoma serovars A, B, and Chave
been sequenced (15, 16). The proteins are highly conserved,
beinginterspersed by four shortvariable domains(VDs I-IV)
whose sequences vary among thedifferent MOMPs. S,erovar-
specific neutralizing mAbs mapto linear epitopes within VDs
I ofthe MOMP ofserovars A and C andVD II of theMOMP
of serovar B (15, 17). We envision that these serovar-specific
MOMP epitopes will ultimately be combined in a synthetic
or recombinant product to form a trivalent trachoma vac-
cine. However, an effective trachoma vaccine will likely rely
on natural boosting of immunized individuals by exposure
to or reinfection with chlamydiae. This requirement for T
cell immunity would not be met by vaccination with pep-
tide antigens consisting only of serovar-specific B cell epi-
topes or through the use of irrelevant carriers, but will re-
quire the incorporation of MOMP-derived Th cell epitopes.
In this report, we identify potentially important Th cell
determinants ofthe MOMP andshow that syntheticcolinear
chimeric peptides composed of MOMP Th and B cell anti-
genic determinants areimmunogenic and stimulate high ti-
tered serovar-specific antibodies reactive with both the na-
tive MOMP and intact chlamydiae. These findings will be
useful for developing a synthetic or recombinant trachoma
vaccine.
Materials and Methods
Chlamydiae.
￿
C. trachomatis serovar A(strainHar-13)wasgrown
in HeLa 229 cells, and elementary bodies (EBs) were purified by
centrifugation in discontinuous Renografin gradients (18).
Purification ofA MOMP
￿
Serovar A MOMP was purified by
preparative SDS-PAGE and electroelution as previously described
(19).
Ikptide Synthesis.
￿
Peptides were synthesized on RapidAmide resin
using a RaMPS (DuPont Co., Wilmington, DE) manual synthe-
sizeror by using an automated synthesizer (430; Applied Biosystems,
Foster City, CA) according to the directions of the manufacturer.
Thesynthesisused pentafluorophenylesters offluorenylmethyloxy-
' Abbreviations used in this paper: AS, amphipathic scores; EB,
elementary body; g.m.t., geometric mean titers; MOMP, chlamydial
major outer membrane protein; PBBS, phosphate-buffered balanced
salt solution; VD, variable domain.
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carbonyl-L amino acids, except forserine and threonine, whereoxo-
benzotriazine esters were used, and arginine, which was coupled
as the symmetric anhydride. Peptides were cleaved from the resin
with trifluoroacetic acid, extracted four times with diethyl ether
and twice with ethyl acetate/diethyl ether (1.5:1). The peptides
were precipitated from ether with waterandthewaterprecipitated
peptides were lyophilized. Soluble peptides were purified by reverse
phase HPLC using a semipreparative C18 ultrasphere column
(Beckman Instruments, Inc., Fullerton, CA) and awater/acetoni-
trile/0.1% trifluoroacetic acid elution gradient . Insolublepeptides
were purified by desalting througha Sephadex G-10 column using
50% acetic acid. Thecomposition ofpeptides was verified by amino
acid analysis.Thecysteine residue wasblocked with a t-butyl group
in all peptides containing this residue.
Mice. Female A/J (H-2'), C57BL/10SnJ (H-2b), BALB/cJ
(H-2d), CBA/J (H-2k), DBA/1J (H-29), and SJL/J (H-2') mice
were purchased from TheJackson Laboratory (Bar Harbor, ME),
and used at 8-12 wk of age.
Immunogenicity of MOMP in Strains of Mice Differing at H-2.
Groups of five mice were immunized intraperitoneally with 0.2
ml CFAcontaining 5 pcg of purified serovar A MOMP. 3 wk after
immunization, mice werebled and sera were assayed by ELISA for
IgG antibodies specific to the MOMP and syntheticpeptides cor-
responding to each of theMOMP VDs. The synthetic peptide an-
tigens used were VD I(residues 61-85), VD II (residues 136-160),
VD III (residues 226-250), the NHa-terminal end of VD IV
(residues 286-310), andtheCOOH-terminalendofVD IV (residues
301-325).
Preparation ofAPC.
￿
Peritoneal exudate cells were elicited by
intraperitoneal injection with 1.0 ml 2.5% oyster glycogen (Type
II; SigmaChemical Co., St. Louis, MO) in 0.01 M sodium phos-
phate, 0.15 M NaCl, pH 7.2 (PBS). Peritoneal exudate cells were
harvested 3-4 d after injection, washed twice in PBS, and irradi-
ated (2,000 rad) in a'3'Cs ti irradiator. Irradiated peritoneal exu-
date cells were washed once and resuspended to 10' cells/ml in
prewarmed phosphate buffered balanced salt solution, pH 7.2
(PBBS),containing 10% FCS (HyClone Laboratories, Logan, UT).
An equal volume ofperitoneal exudate cells (10' cells/ml) and syn-
thetic peptides (1 mg/ml) were mixed and incubated for 1 h at
37°C. These antigen-pulsed peritoneal exudatecells were washed
three times with PBBS andresuspended to a concentration of 10,
cells/ml in Click's medium (20) supplemented with 5% FCS and
50 Rg/mlgentamicin sulfate. Controlperitoneal exudatecellswere
prepared similarly, except cellswere mixed with an equal volume
of medium instead of antigen.
T Cell Proliferation Assays.
￿
A/J mice were immunized intra-
peritoneally with 0.2 ml of CFA containing 5 jig of MOMP on
day0andboosted intraperitoneally 3 wk later with 0.2 ml of IFA
containing 5 pg of MOMP. 2-3 wk after thebooster immuniza-
tion, mice were killed, splenic T cells isolated, and proliferation
assays performed. Nylon wool-passed T cells were prepared (21,
22)from spleens ofmice immunizedwith either serovarAMOMP
in CFA or CFAalone. Approximately5% ofthenylonwool-passed
cells expressed surface Ig*, as determined by staining with FITC-
conjugated goat anti-mouse Ig serum (CooperBiomedical, Inc.,
Malvern, PA). The cells were washed twice with PBBS and re-
suspended to 5 x 106cells/ml in Click's medium. 100 ul of T cell
suspension and 100 jA1 of APC were placed into wells of 96-well
flat-bottomed microtiter plates (Linbro; Flow Laboratories, McLean,
VA) and incubated for 5 d at 37°C and 5% COZ. Cells were
pulsed with 1 IACi/well ['H]thymidine (6.7 Ci/mmol; New En-
gland Nuclear, Boston, MA) forthe final 16 h, then harvestedwith
an automatic cell harvester (Cambridge Technology, Inc., Water-
T Cell Epitopes o£ the Chlamydial Major Outer Membrane Proteintown, MA), and the incorporation of [3H]thymidine into DNA
was measured using a liquid scintillation counter (LS9000; Beckman
Instruments, Inc.). All cultures were done in triplicate. Results are
presented as Acpm (cpm . of experimental cultures minus cpm of
cultures o£ T cells alone).
In Vivo Priming of Th Cells with Synthetic Peptides.
￿
Groups of
five A/J mice were immunized intraperitoneally with 0.2 ml of
CFA containing either 100 wg of synthetic peptide or PBS alone.
3 wk later, mice were immunized intraperitoneally with 0.2 ml
of IFA containing 514g ofpurified MOMP. Mice were bled before
immunization with purified MOMP (day 0) and 12 d after chal-
lenge immunization. Sera were collected and pooled by groups.
The sera were assayed by ELISA for IgG antibodies specific to the
MOMPand to synthetic peptides corresponding to sequences con-
tained within the different MOMP VDs.
Immunogenicity of Colinear Th Cell/B Cell Peptides.
￿
Groups of
five A/J mice were immunized intraperitoneally with 0.2 ml CFA
containing 100 ug of colinear peptides (40 mers) corresponding
to Th cell and B cell sites or the free peptides alone. Colinear pep-
tides were synthesized to combine Th cell epitope residues 106-130
or 331-355 with B cell epitope 66-80 (corresponding to VD I)
and designated as A-8 VD I ('°6ALNIWDRFDVFCTLGATTGY
LKGNS"o66PTTSDVAGLEKDPVAso) and A23 VD I ("'KMK-
SRKSCGIAVGTTWDADKYAVT3ssAPTTSDVAGLEKDPVAeo),
respectively. Mice werebled 3 wk later, and their sera were assayed
by ELISA for IgG antibody reactive with intact EBs, purified
MOMP, and synthetic peptides corresponding to the Th cell and
B cell portions of the colinear peptides.
ELISA.
￿
Microtiter plates (Immulon 2, 96-well, U-bottomed;
Dynatech Laboratories, Inc., Alexandria, VA) werecoated with 100
p,l of purified A MOMP (0.5 i~g/ml), serovar A EBs (10 hg/ml),
or synthetic peptides (5 Fig/ml) in 0.05 M Tris buffer (pH 7.5)
containing 0.15 M NaCl. The microtiter plates were sealed and
incubated overnight at 4°C. Wells were emptied and washed three
times with PBS containing 0.05% Tween 20 (PBSTween) and then
incubated with 200 Al blocking buffer (PBSTween containing 2%
BSA) for 2 h at 37°C. The plates were washed once in PBSTween,
and then 100 ul of immune or control mouse serum diluted in
blocking buffer was added to appropriate wells and incubated for
1.5 h at 37°C. The plates were washed five times with PBSTween,
and a 1 :500 dilution of alkaline phosphatase-conjugated rabbit
anti-mouse IgG (,y chain specific; Zymed Laboratories, San Fran-
cisco, CA) was addedto the wells and the plates incubated for 1 h
at 37°C. After washing, 100 pl of substrate (5 mg p-nitrophenyl
phosphate in 10 ml of0.1 M 2, 2 amino-2-methyl-1, 3-propandiol,
pH 10.3) was added, and the plates incubated for 30 min at 37°C.
The enzymatic reaction was terminated by the addition of 50 JAI
of 5 N NaOH to each well. OD was read at 405 nm. Endpoint
titrations were the highest dilutions of sera giving 0.3 OD units
at 405 nm.
Sequence Analysis.
￿
The primary sequence ofA MOMP was ana-
lyzed by the AMPHI algorithm developed by Margalit et al. (23)
for regions with periodic variation in the hydrophobicity consis-
tent with the formation of an amphipathic a helix. Overlapping
blocks of 11 amino acids were used in the analysis, and Fauchere-
Pliska (24) hydrophobicity values of amino acids were used in the
calculations. Only those segments of the sequence with amphipathic
scores (AS) of eight or greater are shown in the MOMP sequence.
The computer analysis was kindly performed by Dr. Hanah Mar-
galit, Laboratory ofMathematical Biology and LaboratoryofTumor
Cell Biology, National Cancer Institute, National Institutes of
Health, Bethesda, MD. Structural motifs (charged residues or gly-
cine, followed by two or three hydrophobic residues, and then polar
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Figure 1.
￿
Antibody responses of mice of different H-2 haplotypes
immunized with purified serovar A MOMP. Bars represent geometric
mean anti-MOMP IgG titers of pooled sera of five mice after a single
immunization with purified MOMP. The antibody titers for in-
dividual mice are also shown ("). Endpoint titrations were the
highest dilutions of sera giving an absorbance reading of 0.3.
residues or glycine) described by Rothbard and Taylor (25) were
identified by visual inspection of the MOMP primary sequence.
Results
Antibody Response to the MOMP in Mice Differing in H-2
Haplotype. Initially, inbred strains of mice were tested for
their ability to produce an anti-MOMP antibody response.
Six inbred strains of mice of different H-2 haplotype were
immunized with purified A MOMP, and the IgG response
specific to the MOMP was determined by ELISA (Fig. 1).
All strains tested produced IgG geometric mean titers (g.m.t.)
of logto 3.3 or greater after a single immunization, however,
certain strains of mice produced higher titered anti-MOMP
responses (A/J [g.m.t. = logto 4.7], C57BL/10 [g.m.t. _
logto 4.8], and DBA/1 [g.m.t. = logto 4.7]).
The molecular specificity of the anti-MOMP response of
different strains of mice was determined by assaying the IgG
antibody responses to synthetic peptides corresponding to
sequences contained within the four VDs of the MOMP. The
molecular specificity of the anti-MOMP response for each
mouse strain is shown in Table 1. VD I (residues 61-85) and
the NH2-terminal end of VD IV (residues 286-310) were
found to be the immunodominant regions of the MOMP
recognizedby mouse strains differing in H-2 haplotype. CBA
mice responded less intensely to VD I compared with other
strains, whereas C57BL/10 and SJL mice had lower IgG an-
tibody titers specific to the NH2-terminal end of VD IV
than other mouse strains.
To determine whether these same regions ofMOMP were
immunodominant when the protein was presented in its na-
tive state, A/J mice were immunized with formalin-fixed in-
tact serovar A EBs, and their sera were analyzed for antibodies
reactive with peptides corresponding to the different MOMP
VDs. As shown in Table 2, immunization with intact chla-
mydial EBs produced IgG antibody responses primarily reac-Table 1.
￿
Molecular Specificity ofAnti-MOMPAntibody Responses ofDiferent Inbred Strains of Mice Immunized with Serovar A MOMP
ELISA titers are expressed as the reciprocal of pooled serum dilutions giving an absorbance reading of 0.3. Absorbance values of normal mouse
sera were 0.1 or less. Synthetic peptides corresponding to sequences of each VD of serovar A MOMP were used as ELISA antigens. Because
VD IV contains 30 residues, overlapping peptides p286-310 and p301-325, representing the NH2- and COON-terminal portions of the do-
main, respectively, were assayed separately.
tive with synthetic peptides corresponding to VD I and the
NHrterminal end of VD IV Thus, the antibody titer and
molecular specificity of the IgG response were similar after
immunization with intact EBs or purified MOMP, and the
immunogenicity of the contiguous B cell sites located in VD
I and IV of the MOMP did not significantly differ when
MOMP was presented either in its denatured purified form
or native state.
These findings demonstrated that serovar A MOMP VD I
and the NH2-terminal end of VD IV were immunodomi-
nant in mouse strains disparate at H-2 suggesting that Th
cell determinants of the protein that induce B cell responses
to these sites are recognized in association with several MHC
haplotypes. Because mouse strains disparate at H-2 were
capable of producing anti-MOMP antibodies with similar
specificities, we used a single strain (A/J) to further identify
MOMP Th cell epitopes.
Screening ofSynthetic Peptides in T Cell Proliferation Assays.
Our approach was to identify regions of the MOMP con-
taining T cell determinants and then to define these T cell
sites functionally. We first examined the T cell-stimulating
Table 2.
￿
Molecular Specificity ofAnti-MOMP Antibody Responses of A/J Mice Immunized with Serovar A EBs or Serovar A MOMP
VD I
Immunogen
￿
A MOMP
￿
p61-85
A EBS
￿
2,048
￿
1,024
A MOMP
￿
8,192
￿
2,048
VD II
p136-160
16
128
ability of synthetic peptides corresponding to MOMP se-
quences. A series of 25 overlapping peptides (25 mers) that
represented the entire MOMP sequence was synthesized and
tested in T cell proliferation assays. The synthetic peptides
were designated A-1 through A-25. The position of the pep-
tides in relation to their location in the primary sequence
of serovar A MOMP is shown in Fig. 2. Screening for T cell-
proliferative responses was first done using mixtures of syn-
thetic peptides with each group containing equal amounts
of three different peptides. T cells from mice primed with
MOMP responded to five groups of mixed synthetic pep-
tides: A-(1-3), A-(7-9), A(9-11), A-(20-22), and A-(23-25)
(Fig. 3 A) . Peptides contained within each of these groups
were then tested individually in T cell proliferation assays.
MOMPprimed T cells proliferated when cultured with pep-
tides A-2, A3, A7, A-8, A-11, A-22, A23, and A-24 (Fig.
3 B). Because peptides A-2 and A-3, A-7 and A-8, and A-22,
A-23, and A-24 contain overlapping sequences, it is possible
that the T cell-stimulating ability of these peptides resulted
from shared T cell epitope(s) among the peptides in each of
the three groups.
ELISA antibody titer
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VD III
￿
N'-VD IV
￿
C'-VD IV
p226-250 p286-310 p301-325
64
￿
1,024
￿
64
128
￿
1,024
￿
64
ELISA titers are expressed as the reciprocal of pooled serum dilutions giving absorbance of reading of 0.3. Absorbance values of normal mouse
sera were 0.1 or less. Groups of five A/J mice were immunized with 1.3 x 107 IFUs of formalin-killed serovar A EBs or 5 ttg of serovar A
MOMP purified by preparatory SDS-PAGE.
Strain
of mice
H-2
haplotype
VD I
p61-85
VD II
p136-160
ELISA antibody titer
VD III
p226-250
N'-VD IV
p286-310
C'-VD IV
p301-325
A/J a 2,048 64 64 2,048 64
C57BL/10 b 2,048 16 256 256 <16
BALB/c d 2,048 <16 64 1,024 128
CBA k 256 <16 <16 4,096 <16
DBA/1 q 2,048 16 64 1,024 512
SJL s 512 <16 128 128 <161
￿
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Figure 2.
￿
Amino acid sequence of the mature serovar A MOMP
and the locations of overlapping synthetic peptides. Synthetic peptides
consisted of 25 residues each and overlapped by 10 residues. Peptides
were designated A-1 through A-25. The VDs of serovar A MOMP
are also identified: VD I (residues 69-85), VD II (residues 141-162),
VD III (residues 226-239), and VD IV (residues 290-319). VD I is
the location of the serovar A-specific neutralizing site (residues
70-80). Neutralizing serogroup-specific and non-neutralizing species-
specific epitopes have been mapped to VD IV.
Ability ofSynthetic Peptides to Prime Th Cells In Viva
￿
We
next determined whether the synthetic peptides that stimu-
lated in vitro T cell-proliferative responses were capable of
functioning as Th cell epitopes. For those studies, we used
an in vivo assay described by Milich et al. (26) for the
identification of Hepatitis B virus nucleocapsid Th cell epi-
A-3 -
A-9
207
￿
Su et al.
topes. A/J mice were immunized with synthetic peptides that
stimulated in vitro T cell-proliferative responses (A-2, A-3,
A7, A8, A11, A22, A23, and A24), and 3 wk laterwere
boosted with purified MOMP Mice were bled before boosting
with MOMP (day 0) and 12 d after the booster immuniza-
tion. Sera were pooled by groups and assayed by ELISA for
IgG antibody specific to MOMP, synthetic peptides corre-
sponding to sequences contained within VD I-IV, and the ho-
mologous immunizing peptide. The rationale of this ex-
perimental approach is that memory Th cells are primed by
immunizing with the synthetic peptide and are recalled to
induce B cells to produce MOMP-specific IgG antibody after
booster immunization with the native molecule. Immuno-
logical recall by native MOMP indicates that the peptide rec-
ognition site is relevant to the native antigen. By assaying
IgG responses to defined synthetic peptide sequences of the
protein, it is possible to define the specificity of the Th cell
response at the molecular level.
The IgG antibody responses of A/J mice primed with syn-
thetic peptides and challenged withpurified MOMP are shown
in Fig. 4. Mice primed with CFA alone and boosted with the
MOMP in IFA did not produce antibody specific to MOMP
or to synthetic peptides corresponding to VD sequences.
These results demonstrated that immunization with 5 Ag
of MOMP in IFA was a suboptimal immunizing dose that
was incapable of inducing an IgG anti-MOMP response. With
the exception of peptide A3, each of the synthetic peptides
tested effectively primed A/J mice to produce IgG antibodies
specific to the MOMP. However, only peptides A-7, A8,
and A23 primed mice to produce significant amounts of IgG
antibodies specific to B cell determinants located within
VD I and the NH2-terminal end of VD IV These same sera
did not possess significant levels of antibodies reactive with
sequences corresponding to VD II, VD III, or the homolo-
gous priming peptide. These results indicated that peptides
A-7, A8, and A23 contain Th cell epitopes that direct B
cell clones to produce antibodies specific to VD I and VD
IV. Peptides A-11 and A22 also primed mice to produce an-
tibodies reactive with VD IV, suggesting that MOMP con-
Figure 3.
￿
Proliferative responses of MOMP-
primed T cells to overlapping synthetic peptides (25
mers) corresponding to the entire serovar A MOMP
sequence. (A) Proliferative responses to pooled syn-
thetic peptides. (B) Proliferative responses to indi-
vidual peptides. A/J mice were immunized intra-
peritoneally with either 5 tag of serovar A MOMP
in CFA or CFA alone. 3 wk after immunization,
splenic T cells were isolated and cultured with ei-
ther pools of synthetic peptides or individual syn-
thetic peptides. Proliferative responses were mea-
sured after 5 d of in vitro culture, as described in
Materials and Methods. No antigen backgrounds
(media alone) were: A, 2,190 cpm; B, 4,037 cpm.
Proliferative responses to the various peptide an-
tigens of T cells isolated from mice immunized
with CFA alone were: A, Acpm <1,000, except
A-(7-9), with Acpm = 1,850; B, Acpm <500, ex-
cept A-2, with Ocpm = 4,056.tains multiple Th cell sites capable of directing antibody re-
sponses to this domain. Considerable experimental variation
was observed in the antibody responses specific to MOMP
in mice primed with peptide A-7 . The reason for this ex-
perimental variation is unknown, however, peptide A-7 may
contain a partial Th cell determinant (see Discussion) that
could, in part, account for these findings.
Peptides A-11, A-22, and A-24 appeared to contain both
Th andB cell determinants since mice immunized with these
peptides produced high titered antibodies to the homologous
immunizing peptide before immunization with the native
MOMP . The B cell determinants associated with these pep-
tides are not likely relevant to chlamydial vaccine develop-
ment since they are not known to be surface accessible on
intact serovar AEBs. Likewise, it is unlikely that the Th cell
determinants present in these peptides would be useful com-
ponents of a chlamydial vaccine since they do not provide
Th cell function for antigenic sites located in VD I or IV
Sera from mice primed with peptideA2 contained antibodies
specific to MOMP, however, these antibodies reacted only
poorly with VD I and IV sequences and did not recognize
the homologous immunizing peptide suggesting that the
antibody was specific toB cell sites located outside theMOMP
VDs or reacts with structurally dependent VD determinants
that are not present in the short synthetic peptide antigens .
Collectively, the above results indicate that peptides A-8
and A23 contain Th cell epitopes and that these epitopes
function in a cooperative and directional manner in inducing
B cell clones to produce antibodies specific to surface-exposed
neutralizing determinants located inMOMP VD I and IV
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Figure 4 .
￿
Synthetic peptides containing T cell de-
terminants of MOMP primed mice to produce an
augmented anti-MOMP IgG response in vivo.
Groups of five A/J mice were primed with syn-
thetic peptides and then challenged with purified
MOMP . Mice were bled before booster immuniza-
tion (day 0) and 12 d after challenge immunization .
Sera were collected, pooled, and analyzed by ELISA
for IgG antibody specific to MOMP; synthetic pep-
tides corresponding to VD I, II, III, and the NH2-
terminal end of VD IV; and the homologous im-
munizing peptide. Endpoint titers are expressed as
the reciprocal of the 1092 of the highest serum dilu-
tion giving an absorbance reading of 0.3 . Data are
the mean titers of two experiments for all peptides
except A-8 and A-23, which were tested three
times.
Since peptides A-8 and A-23 primed mice to produce higher
titered antibodies specific to these important B cell sites, we
chose them for further investigation .
Immunogenicity ofColinear chimeric Peptides Containing Th
andB Cell Determinants. To test conclusively that peptides
A8 and A23 contained Th cell epitopes, we synthesized them
as colinear peptides with the VD I sequence and used them
to immunize mice . PeptideA8VD I was colinearly synthe-
sized to contain residues 106-130 and 66-80, and peptideA23
VD I was colinearly synthesized to contain residues 331- 355
and 66-80 . Groups of five A/J mice were immunized with
the colinear peptides A-8 VD I, A23 VD I, or the free pep-
tides A8, A23, orVD I . Their sera were tested byELISA for
IgG antibody reactive against intact EBs, purified MOMP,
a synthetic peptide corresponding to the VD I sequences,
and synthetic peptides containing T cell sites only (Fig. 5) .
Mice immunized with peptides A-8 (106-130), A-23 (331-
355), or VD I (63-83) did not produce antibodies reactive
with the purified MOMP, intact EBs, or VD I sequences.
In contrast, when mice were immunized with the colinear
peptides A-8 VD I or A-23 VD I, significant antibody re-
sponses reactive with intact EBs, MOMP, and the synthetic
peptide corresponding to VD I were detected . The colinear
peptideA8 VD I was a superior immunogen since mice im-
munized with this peptide consistently produced higher ti-
tered antibodies reactive with EBs, MOMP, and VD I . Sera
from mice immunized with A8 VD I and A23 VD I pep-
tides did not react with the synthetic peptides A8 or A23,
demonstrating that the antibody response elicited by colinear
peptides was directed at B cell sites located in the VD I se-
T Cell Epitopes of the Chlamydial Major Outer Membrane ProteinDiscussion
209
￿
Su et al.
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quence. Importantly, the VD I-specific antibodies produced
after immunization with the colinear peptides reacted with
both intact EBs and purified MOMP demonstrating that the
antibody specificity produced by these synthetic peptides is
relevant to the native MOMP structure.
The C. trachomatis MOMP is a major target antigen for
the development of a trachoma vaccine. A MOMP-based vac-
cine will require either a recombinant or synthetic antigen
since it is not realistic to obtain the quantities of native MOMP
that would be necessary for vaccination. A synthetic triva-
lent antigen composed of trachoma serovar-specific MOMP
epitopes is a credible vaccine strategy. However, it is unlikely
that these B cell determinants alone will be sufficient since
they lack MOMP-derived Th cell determinants capable of
recalling antigen-specific immune responses; this will most
likely be a requirement ofa successful trachoma vaccine. The
goal of this study was to identify Th cell epitopes of the
MOMP that direct B cell clones to produce antibodies specific
to serovar-specific epitopes. These Th epitopes could then be
incorporated with neutralizing B cell epitopes in a peptide-
based trachoma vaccine.
Initially, we investigated the immunogenicity of the purified
MOMP in six inbred mouse strains differing at H-2 to deter-
A UOUP
Figure 5.
￿
Antibody responses of
A/J mice after immunization with
chimeric TIB cell peptides or free
peptides. Five mice per group were
immunized intraperitoneally with
100 kg of peptide in CFA. 3 wk
after immunization, the mice were
bled, their sera pooled, and then
analyzed by ELISA. Mouse anti-
sera were (A) anti-A-8 VD I, (")
anti-A-23 VD I, (A) anti-VD-1,
(Q) anti-A-8, and (O) anti-A-23.
These sera were analyzed by ELISA
against (A) intact serovar A EBs,
(B) purified serovar A MOMP, (C)
peptide VD I (residues 61-85),
and (D) free peptides A8 and
A-23. Mouse anti-A-8 and anti-A-8
10
￿
12
￿
14
￿
VD I were tested against peptide
A-8, and mouse anti-A-23 and
anti-A-23 VD I were tested against
Free Peptide
￿
peptide A-23. Mice immunized
with A-8 VD I or A-23 VD I
produce high titered antibodies
reactive with EBs, MOMP, and
VD I. Anti-A-8 VD I or A-23
VD I sera did not react with the
A-8 or A-23 peptides, demon-
strating that the antibody response
was directed at the VD I sequence
of the chimeric peptides. Mice im-
munized with the VD I peptide
did not produce antibodies reactive
with the VD I peptide, demon-
strating that this sequence alone
was not immunogenic.
mine if variation in antibody response to the MOMP was
influenced by MHC haplotype. These studies were done to
identify high responder strains that would then be selected
for further investigations to identify MOMP Th cell deter-
minants. Our findings showed that inbred strains differing
at H-2 produced significant antibody responses to the MOMP
and that VD I and the N142-terminal end of VD IV were
the immunodominant B cell sites recognized by strains of
mice disparate at H-2. VDs I and IV were also found to be
immunodominant when intact EBs were used as immunogens.
At the surface of serovar A EBs, portions of VD I and VD
IV are exposed, whereas VD II and III are not exposed (15;
and our unpublished observations). The surface exposure of
these domains likely contributes to their immunogenicity on
EBs, but it is unclear why these same VDs are also im-
munodominant in the purified protein. Nevertheless, our
findings clearly demonstrate that linear determinants contained
within serovar A MOMP VD I and VD IV are immuno-
dominant B cell epitopes that are recognized in association
with multiple H-2 haplotypes.
To identify T cell sites ofthe MOMP, 25 overlapping pep-
tides representing the entire primary sequence of serovar A
MOMP were synthesized and tested in T cell proliferation
assays. Our findings demonstrated that eight synthetic pep-
tides contained T cell epitopes. We compared our experimental
data with the AMPHI (23) and the motif (25) methods forFigure 6 .
￿
Schematic diagram
comparing experimental data
defining MOMP T cell epitopes
with those identified using
AMPHI and motif T cell epitope
prediction algorithms . The pri-
mary sequences of serovars A, C,
and B MOMP are shown, The A
MOMP sequence is presented as
the prototype sequence for com-
parative purposes. Dots in the B
and C MOMP sequences represent
identical amino acid residues with
serovar A MOMP. T cell sites
predicted by the AMPHI al-
gorithm and motif methods are
identified in the serovar A MOMP
sequence. Helical periodicity in the
sequence is denoted by 0 or 1, and
the amphipathic scores are given
below the individual amphipathic
segments. T cell motifs (charged
residue or glycine, followed by
two or three hydrophobic residues
and then polar residues or glycine)
are underlined in the A MOMP
sequence . Those synthetic peptides
that produced positive proliferative
responses in MOMP-primed T cell assays are shown below their corresponding sequences in the primary MOMP sequences. Each of the peptides
contained T cell sites predicted by one or both of the prediction methods. The majority of MOMP peptides containing T cell determinants map
to regions of the molecule that are conserved among different C. trachomatis MOMP genes . The MOMP VDs are identified in the sequences by
the boxes. VD I of serovar A MOMP is the location of neutralizing serovar-specific antigenic determinants. VD II and VD III are not surface
accessible on intact serovar A EBs. VD IV is surface accessible and is the location of serogroup-specific neutralizing antigenic determinants .
the prediction of likely T cell sites of theMOMP molecule
(Fig . 6) . Both methods predicted a rather large proportion
of the molecule as potential T cell sites ; 35% of the primary
sequence contained T cell motifs and 21% amphipathic seg-
ments . Six of the eightMOMP synthetic peptides that pro-
duced positive T cell proliferative responses (A2, A-3, A-7,
A-8, A-11, and A22) contained amphipathic segments with
AS of eight or greater. All eight of the peptides possessed
T cell motifs (charged residues or glycine followed by two
or three hydrophobic residues and then polar residues or gly-
cine) in their sequences . Peptides A-2, A7, and A8, which
correspond to regions ofMOMP that produced the highest
amphipathic scores (residues 17-37, AS = 45 ; and 107-116,
AS = 22 .2), also were ones of those that produced the
strongestT cell proliferative responses . In contrast, peptides
corresponding to the portion of theMOMP sequence con-
taining the most prominent arrangement of T cell motifs
(residues 222-241) were negative in MOMP-primed T cell
proliferation assays. This cluster of predicted T cell motifs
is located inVD III, the least variable domain of theMOMPs
and the only domain to which B cell sites have not mapped .
T cell sites that map to this domain would be of interest since
they would provide antigenic diversity of theMOMP at the
T cell level . It is possible that this site might be immuno-
genic in mouse strains different at H-2 or in other species .
In our attempts to define peptides that provide functional
Th cell responses, we used an in vivo assay that depends on
the priming peptide to augment IgG antibody responses
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specific to MOMP after booster immunization . We found
that peptides A-7, A-8, and A-23 primed mice to produce
high titered antibodies specific to the immunodominant B
cell sites located in VD I and IV of the protein . It is likely
that peptides A-7 and A-8 carry a common immunodominant
Th cell epitope since they are overlapping peptides that share
the sequence 1°6ALNIWDRFDVIIs, which has the second
highest amphipathic score (AS = 22.2) in theMOMP pri-
mary sequence . It is interesting to note that in vivo priming
with peptide A-7 produced more variable results in its ability
to augment antibody responses to VD I and VD IV than
those observed with peptideA8 . This difference may result
because peptide A8 contains the entire predicted T cell am-
phipathic segment (residues 107-116), whereas peptide A7
is missing theCOOH-terminal phenylalanine residue of the
predicted site.
To directly demonstrate that peptides A8 and A23 con-
tained functional Th cell epitopes, we synthesized these pep-
tides as colinear peptides with theVD I sequence and tested
their immunogenicity. Our findings clearly demonstrate that
the T/B cell colinear peptides were highly immunogenic . A
single immunization with the peptides produced high titered
antibodies specific to the serovar-specific B cell determinants
located inVD 1 . More importantly, - these antibodies were
reactive with both the MOMP and intact serovar A EBs,
demonstrating that they recognizeVD I 'determinants in the
native protein. We have shown that peptides A-8 and A-23
are capable of directing B cell clones to produce antibodiesspecific to different sites (VD I and VD IV) on serovar A
MOMP. Further studies are needed to determineif these Th
cell determinants are capable of directing B cell clones to pro-
duce antibodies specific to sites located in the MOMP VDs
of otherC. trachomatis serovars. The Th cell epitopes located
in peptides A-8 and A-23 likely have common T cell anti-
genic properties that are shared with other MOMPs since
sequences contained within thesepeptides are conserved among
different MOMP genes (Fig. 6) (15, 16, 27, 28). A more exact
descriptionof the molecular structure ofMOMP Th cell de-
terminants contained within peptides A8 and A-23 will re-
quire fine mapping studies using nested sets of overlapping
peptides. Additionally, it will be important to determine their
immunogenicity in congeneic strains ofmice differing at H-2
to describe precisely the genetic restriction ofthe T cell reper-
toire capable of responding to these determinants.
One of the concerns facing peptide-based vaccines is their
ability to induce effective immunity against the pathogen.
Peptide vaccines corresponding to B cell sites alone are often
ineffective immunogens, whereas peptides corresponding to
B cell sites conjugated to irrelevant carriers may be ineffec-
tive in priming or boosting immunity upon re-exposure to
the pathogen since they are incapable of inducing functional
Th cell activity to the native antigen. In attempts to circum-
vent these potential problems in the development of a syn-
thetic peptide vaccine for trachoma, we have identified Th
cell determinants of the MOMP and incorporated these de-
terminants as chimeric peptides with an immunodominant
MOMP B cell determinant. In theory, these chimeric pep-
tides should be capable of either priming or boosting neu-
tralizing serovar-specific antibody responses upon natural ex-
posure or reinfection with chlamydiae. Studies are planned
to evaluate the immunogenicity of these chimeric peptides
in primates and to determine their vaccine potential in a pri-
mate model of C. trachomatis infection.
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